Literature DB >> 11193148

The value of transgenic models for the study of neurodegenerative diseases.

D L Price1, P C Wong, A L Markowska, M K Lee, G Thinakaren, D W Cleveland, S S Sisodia, D R Borchelt.   

Abstract

Transgenic animal models are useful in studying the features of APP- and PS1-linked FAD and SOD1-linked FALS. These models help to investigate the nature of the cellular/biochemical/molecular alterations in neural tissue; the character and evolution of neuronal and/or glial abnormalities; the ways mutant proteins cause damage to neurons; and the biochemical pathways associated with cell death. New technologies will help to define changes in a variety of genes/gene products and the events and conformational changes in mutant proteins that are implicated in pathogenic cascades. It is hoped such study will result in novel treatments for testing in transgenic models that can then be translated into new treatments for human neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193148     DOI: 10.1111/j.1749-6632.2000.tb06920.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI.

Authors:  Joseph J Gallagher; Xiaowei Zhang; Gregory J Ziomek; Russell E Jacobs; Elaine L Bearer
Journal:  Neuroimage       Date:  2012-02-10       Impact factor: 6.556

Review 3.  Heterogeneity of CNS myeloid cells and their roles in neurodegeneration.

Authors:  Marco Prinz; Josef Priller; Sangram S Sisodia; Richard M Ransohoff
Journal:  Nat Neurosci       Date:  2011-09-27       Impact factor: 24.884

Review 4.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

5.  Memory deficits due to familial British dementia BRI2 mutation are caused by loss of BRI2 function rather than amyloidosis.

Authors:  Robert Tamayev; Luca Giliberto; Wei Li; Cristina d'Abramo; Ottavio Arancio; Ruben Vidal; Luciano D'Adamio
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

Review 6.  Axonal transport defects in neurodegenerative diseases.

Authors:  Gerardo A Morfini; Matthew Burns; Lester I Binder; Nicholas M Kanaan; Nichole LaPointe; Daryl A Bosco; Robert H Brown; Hannah Brown; Ashutosh Tiwari; Lawrence Hayward; Julia Edgar; Klaus-Armin Nave; James Garberrn; Yuka Atagi; Yuyu Song; Gustavo Pigino; Scott T Brady
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

7.  Actions of β-amyloid protein on human neurons are expressed through the amylin receptor.

Authors:  Jack H Jhamandas; Zongming Li; David Westaway; Jing Yang; Simran Jassar; David MacTavish
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

8.  Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses.

Authors:  Chi-Cheng Wu; Faisal Chawla; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

9.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

Review 10.  APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Authors:  Leslie Crews; Edward Rockenstein; Eliezer Masliah
Journal:  Brain Struct Funct       Date:  2009-11-29       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.